According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
Several other research analysts have also recently issued reports on the stock. Wedbush reissued a “buy” rating and set a $36.00 target price on shares of Allena Pharmaceuticals in a report on Tuesday, July 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Spero Therapeutics in a report on Thursday, May 9th. ValuEngine raised shares of Vistra Energy from a “hold” rating to a “buy” rating in a report on Wednesday, July 3rd. Credit Suisse Group cut their price objective on shares of Athene from $67.00 to $57.00 and set an “outperform” rating for the company in a report on Tuesday, May 21st. Finally, BidaskClub raised shares of Zillow Group from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 2nd. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Aimmune Therapeutics presently has an average rating of “Hold” and an average target price of $46.43.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.07. Sell-side analysts forecast that Aimmune Therapeutics will post -3.77 EPS for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AIMT. Cable Hill Partners LLC increased its holdings in Aimmune Therapeutics by 81.7% in the first quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 500 shares in the last quarter. Manchester Capital Management LLC purchased a new position in Aimmune Therapeutics in the first quarter valued at $27,000. Pearl River Capital LLC purchased a new position in Aimmune Therapeutics in the first quarter valued at $28,000. Marshall Wace North America L.P. purchased a new position in Aimmune Therapeutics in the first quarter valued at $32,000. Finally, Advisor Group Inc. increased its holdings in Aimmune Therapeutics by 84.6% in the fourth quarter. Advisor Group Inc. now owns 1,737 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 796 shares in the last quarter. 76.12% of the stock is owned by institutional investors.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Recommended Story: How to trade on quiet period expirations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.